Hair loss hope: new drink targets shedding from popular Weight-Loss meds
NCT ID NCT07484061
First seen Mar 20, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a drinkable nutraceutical supplement called Olistic Next Women to see if it can reduce hair loss in women who are taking GLP-1/GIP receptor agonists (like Ozempic or Mounjaro). About 40 women over age 35 who recently started these drugs will take either the supplement or a placebo daily for 6 months. Researchers will measure hair shedding using patient reports and a comb-and-wash test to see if the supplement helps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELOGEN EFFLUVIUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grupo Dermatologico Y Estetico Pedro Jaen S.A.
RECRUITINGMadrid, Madrid, 28006, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.